2021
DOI: 10.1016/j.radonc.2021.06.030
|View full text |Cite
|
Sign up to set email alerts
|

A multicentre retrospective review of SABR reirradiation in rectal cancer recurrence

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
11
1

Year Published

2022
2022
2024
2024

Publication Types

Select...
6
1
1

Relationship

0
8

Authors

Journals

citations
Cited by 12 publications
(12 citation statements)
references
References 23 publications
0
11
1
Order By: Relevance
“…In patients who choose not to pursue or are not eligible for surgery, stereotactic body radiotherapy combined with systematic chemotherapy, although not curative, may achieve durable disease control for some. 7…”
Section: Locally Advanced and Recurrent Rectal Cancermentioning
confidence: 99%
See 1 more Smart Citation
“…In patients who choose not to pursue or are not eligible for surgery, stereotactic body radiotherapy combined with systematic chemotherapy, although not curative, may achieve durable disease control for some. 7…”
Section: Locally Advanced and Recurrent Rectal Cancermentioning
confidence: 99%
“…In 2024, pelvic exenteration is considered the standard of care for selected patients with locally advanced and recurrent rectal cancer. In patients who choose not to pursue or are not eligible for surgery, stereotactic body radiotherapy combined with systematic chemotherapy, although not curative, may achieve durable disease control for some 7 …”
Section: Locally Advanced and Recurrent Rectal Cancermentioning
confidence: 99%
“…For locally advanced or advanced rectal cancer, distant metastasis is the most common cause of death, and the lung is the most likely site, followed by the liver (13,14). However, if local recurrence occurs without surgery, the 5-year overall survival is about 4% (15)(16)(17)(18)(19)(20).…”
Section: Discussionmentioning
confidence: 99%
“…The RAPIDO trial shows that SCRT can signi cantly reduce the rate of distant metastasis (19.8% vs. 26.6%) and increase the pCR rate (27.7% vs. 13.8%) compared with the standard LCRT [20]. Besides, more recently studies show that re-irradiation with stereotactic ablative radiotherapy (SABR, 30 Gy/5 Fx) is well tolerated and achieved high local control rates, the 2-year LC rate was 68.2-69.0% and 0-3% of patients developed grade 3 toxicities [21][22][23][24]. Thus, hypofractionated radiation in 5 fractions is a potential treatment option for LRRC.…”
Section: Introductionmentioning
confidence: 99%